STOCK TITAN
  1. Home
  2. Sec-filings
  3. EWTX
  4. [Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity

Edgewise Therapeutics Board Member Gets $440K Stock Option Grant

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Edgewise Therapeutics (EWTX) reported a Form 4 filing disclosing insider trading activity by Director Jonathan D. Root. On June 16, 2025, Root was granted 30,000 stock options with the following key terms:

  • Exercise price: $14.68 per share
  • Vesting schedule: 100% vesting on the earlier of June 16, 2026, or the day before the 2026 annual stockholder meeting
  • Expiration date: June 16, 2035
  • Ownership type: Direct

The stock options represent the right to purchase 30,000 shares of Edgewise Therapeutics common stock. The transaction was executed under standard compensation arrangements for directors, with zero cost basis for the options grant. The filing was completed by John R. Moore as attorney-in-fact for Jonathan Root on June 18, 2025.

Positive

  • None.

Negative

  • None.
Insider ROOT JONATHAN D
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 30,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 30,000 shares (Direct)
Footnotes (1)
  1. [object Object]
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ROOT JONATHAN D
(Last) (First) (Middle)
C/O EDGEWISE THERAPEUTICS, INC.
1715 38TH STREET
(Street)
BOULDER CO 80301
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $14.68 06/16/2025 A 30,000 06/16/2026(1) 06/16/2035 Common Stock 30,000 $0.00 30,000 D
Explanation of Responses:
1. 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders.
Remarks:
/s/ John R. Moore Attorney-in-Fact for Jonathan Root M.D. 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many stock options did EWTX director Jonathan Root receive on June 16, 2025?

Jonathan Root received 30,000 stock options (right to buy) of EWTX common stock on June 16, 2025, with an exercise price of $14.68 per share.

What is the vesting schedule for EWTX director Jonathan Root's stock options granted in June 2025?

The stock options will become 100% vested on the earlier of: (i) June 16, 2026, or (ii) the business day prior to the 2026 annual meeting of stockholders.

When do Jonathan Root's EWTX stock options expire?

The stock options granted to Jonathan Root expire on June 16, 2035, ten years after the grant date.

What is the exercise price of EWTX stock options granted to director Jonathan Root in June 2025?

The exercise price of the stock options granted to Jonathan Root is $14.68 per share.

What position does Jonathan Root hold at EWTX according to the Form 4 filing?

According to the Form 4 filing, Jonathan Root serves as a Director of Edgewise Therapeutics, Inc. (EWTX).